Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.03 and traded as high as $0.07. Mateon Therapeutics shares last traded at $0.07, with a volume of 76,720 shares trading hands.
Mateon Therapeutics Stock Performance
The business has a 50-day moving average of $0.04 and a two-hundred day moving average of $0.04.
About Mateon Therapeutics
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Further Reading
- Five stocks we like better than Mateon Therapeutics
- Options Trading – Understanding Strike Price
- Homebuilders in Freefall: Bargain Opportunity or Falling Knife?
- Expert Stock Trading Psychology Tips
- The 3 Most Talked About Investments on WallStreetBets Right Now
- Financial Services Stocks Investing
- Analyst Targets Signal More Growth in CrowdStrike Stock
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
